2/28/2023 – Awakn Life Sciences Signs Its Fourth Licensing Partnership Agreement in North America, and First in California

2/21/2023 – Awakn Life Sciences Signs Its First Licensing Partnership Agreement in Europe

2/14/2023 – Awakn Life Sciences Announces the Opening of Its Fourth Clinic

2/9/2023 – Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology

2/8/2023 – Awakn Life Sciences Responds to OTC Markets Request on Recent Promotional Activity

2/7/2023 – Awakn Life Sciences Granted Fast-Track Designation from UK Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder

1/24/2023 – Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect